Centralising Ethical Review: Legal Questions Arising from ICMR’s Single Ethics Committee Initiative for Clinical Trials

The Indian Council of Medical Research has announced a policy shift that seeks to reduce the time required for obtaining ethical clearance for clinical investigations by introducing a centralized, single ethics review system that would replace the prevailing model of multiple independent committee assessments across the nation. Proponents of the initiative argue that the existing fragmented ethics review architecture often produces redundant evaluations, inconsistent feedback, and protracted waiting periods that collectively impede the timely commencement of essential medical research projects that aim to address pressing public health challenges. By consolidating the ethical oversight function under a single national committee, the Council anticipates achieving greater uniformity in the application of ethical standards, expediting decision‑making timelines, and fostering a more predictable regulatory environment for investigators, sponsors, and institutional partners engaged in clinical trial activities. The proposed reform also seeks to address concerns that duplicated ethical reviews consume scarce resources, duplicate administrative burdens, and generate conflicting recommendations that may force researchers to navigate complex reconciliation processes before receiving final approval to commence studies. Critics caution that centralising ethical review authority could concentrate decision‑making power, raise questions about accountability, and potentially diminish the capacity of local ethics committees to consider site‑specific contextual factors, cultural sensitivities, and community engagement imperatives that are often integral to ethically sound research design. Given the national scope of the initiative, the move is poised to influence the broader regulatory landscape governing clinical research, prompting stakeholders to evaluate how the single ethics review framework will intersect with existing statutory provisions, institutional responsibilities, and the overarching goal of safeguarding participant welfare while facilitating scientific advancement.

One question is whether the Council possesses the statutory competence to prescribe a single national ethics review mechanism, and the answer may depend on the breadth of the empowering provisions that currently delegate authority over clinical research oversight to the Council. If the enabling legislation is interpreted narrowly, the Council’s action could be viewed as an overreach requiring amendment or separate rulemaking, whereas a broader reading might validate the initiative as an exercise of delegated legislative power.

Perhaps the more important legal issue is whether the shift to a single committee preserves the procedural safeguards traditionally guaranteed by multiple independent reviews, including the right of applicants to be heard and to receive reasoned decisions. If the centralized body fails to provide adequate opportunity for parties to address site‑specific concerns, affected stakeholders might argue that the policy infringes upon principles of natural justice that are embedded in administrative law.

Another possible view is that the single ethics review system, if perceived as an administrative action with binding effect, could be subject to judicial review on grounds of illegality, procedural impropriety, or violation of the constitutional right to health. A court evaluating a challenge would likely examine whether the Council acted within the limits of its delegated authority, whether it observed the rule‑making procedure prescribed by law, and whether the outcome respects the balance between efficient research facilitation and participant protection.

Perhaps the constitutional concern is whether centralising ethical approval could dilute the safeguards that protect research participants’ autonomy, informed consent, and right to privacy, which are recognized as components of the right to life and personal liberty. If the single review mechanism does not incorporate robust checks for participant protection, affected individuals might seek recourse through public‑interest litigation asserting that the policy contravenes the fundamental right to dignity.

The administrative‑law perspective may also focus on the need for clear procedural guidelines, transparent criteria for approval, and mechanisms for appeal, because absent such safeguards the single ethics review system could be challenged as arbitrary or disproportionate. A fuller legal assessment would require clarification on whether the Council intends to issue a binding regulation, an advisory recommendation, or a statutory amendment, as each alternative carries distinct implications for enforceability, oversight, and the scope of judicial scrutiny.

Finally, the policy could stimulate a re‑examination of the broader regulatory architecture governing clinical research, prompting legislators to consider whether a harmonised national ethics framework should be codified to ensure consistency, accountability, and alignment with international ethical standards. Such legislative deliberations would themselves be subject to scrutiny under constitutional guarantees of equality and non‑discrimination, especially if the new regime were to affect differently situated research institutions or regional ethics committees.